A New Approach for the Treatment of COPD and Lung Cancer using Inhaled Retrometabolic HSP90 Inhibitors

使用吸入逆代谢 HSP90 抑制剂治疗 COPD 和肺癌的新方法

• 批准号: nhmrc : 1038895
• 负责人: A/Pr Christopher Burns
• 金额: $ 42.56万
• 依托单位: The Walter and Eliza Hall Institute of Medical Research
• 依托单位国家: 澳大利亚
• 项目类别: Development Grants
• 财政年份: 2012
• 资助国家: 澳大利亚
• 起止时间: 2012-01-01 至 2015-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/new-approach-treatment-hsp90-inhibitors/111227
• 关键词: New; Approach; Treatment; COPD; Lung

The inflammatory lung disease Chronic Obstructive Pulmonary Disease (COPD) is a major disease burden in Australia with over 1 million sufferers and being the fourth biggest killer. Lung cancer is one of the most difficult cancers to treat with 5-year survival rates being below 20%. There is a pressing need for new therapies to treat these diseases and this project will develop new drugs designed to inhibit an underlying mechanism present in both diseases, with minimal side-effects.

炎症性肺病慢性阻塞性肺病（COPD）是澳大利亚的一个主要疾病负担，患者超过100万，是第四大杀手。肺癌是最难治疗的癌症之一，5年生存率低于20%。迫切需要新的疗法来治疗这些疾病，该项目将开发旨在抑制这两种疾病中存在的潜在机制的新药，副作用最小。